<DOC>
	<DOCNO>NCT00144248</DOCNO>
	<brief_summary>The objective study evaluate steady-state clearance nevirapine among HIV-1 positive patient hepatic fibrosis , examine whether degree hepatic impairment influence clearance .</brief_summary>
	<brief_title>A Pharmacokinetic Study Assess Nevirapine Viramune Levels HIV Infected Patients With Impaired Hepatic Functions</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>INCLUSION 1 . Male female subject &gt; =18 year age HIV1 infection chronic liver disease reflect documented biopsy hepatic fibrosis present . 2. . Participants must receive nevirapine 200 mg twice daily part stable ARV regimen minimum 6 week prior trough level sample collection . b . Participants receive nevirapine 400 mg daily part stable ARV regimen minimum 6 week , willing switch nevirapi0 mg twice daily minimum 14 day prior trough collection . 3 . Participants must uoxylin Eosin ( H E ) stain slide one trichrome stain pathology slide available time enrollment . There time restriction liver biopsy slide pathologically confirm presence cirrhosis . The presence cirrhosis must document liver biopsy report . EXCLUSION 1 . Current ( within past 4 week ) HIV antiviral therapy NNRTI 's . 2 . Concurrent use ( within past 7 day ) follow : 1 . Systemic azole antifungal agent ( fluconazole , itraconazole , ketoconazole , etc . ) 2 . Clarithromycin 3 . Rifampin 4 . St John 's Wort 3 . Inability provide blood sample . 4 . Patients evidence hepatic encephalopathy Grade 1 5 . Patients renal failure require dialysis . 6 . Pregnant and/or breast feeding women..</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>